Skip Navigation LinksHome > November 2013 - Volume 19 - Issue 12 > Impact of JC Virus Antibody Testing in Patients with Crohn's...
Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000437043.36338.21
Original Clinical Articles

Impact of JC Virus Antibody Testing in Patients with Crohn's Disease with Loss of Response to Infliximab: A Markov Model

Scott, Frank I. MD, MSCE*,†,‡; Osterman, Mark T. MD, MSCE*,‡; McConnell, Ryan A. MD; Lorusso, Monica MD§; Aberra, Faten MD, MSCE*,‡; Kerner, Caroline MD, MSCE*,‡; Lichtenstein, Gary R. MD*,‡; Lewis, James D. MD, MSCE*,†,‡

Supplemental Author Material
Collapse Box

Abstract

Background:

The optimal treatment strategy for patients with Crohn's disease who have loss of response to the anti–tumor necrosis factor α medication infliximab is uncertain. Natalizumab has an alternative mechanism of action, but its use has been limited by the risk of progressive multifocal leukoencephalopathy. In this study, we performed a decision analysis assessing the impact of JC virus (JCV) antibody testing and natalizumab utilization for loss of response to infliximab.

Methods:

We constructed a Markov model to assess the difference between unscreened natalizumab use (option 1), JCV antibody testing with natalizumab when appropriate (option 2), and second anti–tumor necrosis factor α use (option 3). The base case was a 35-year-old man with severe Crohn's disease with loss of response to infliximab. The time horizon was 3 years. Results are reported in quality-adjusted life years (QALYs). Deterministic and probabilistic analyses were conducted. Markov analysis using a cohort of 5000 individuals was performed. The impact of JCV antibody status on outcomes in this model was assessed.

Results:

Option 2 was the preferred strategy (2.0880 QALYs), followed by option 1 (2.0875 QALYs) and option 3 (2.0808 QALYs). Patients in option 2 required fewer surgeries compared with option 3. Previous JCV infection was associated with reduced QALYs with all options that allowed for natalizumab use.

Conclusions:

JCV antibody testing and subsequent treatment selection yield improved outcomes over natalizumab without testing or using only a second anti–tumor necrosis factor α in all patients.

Copyright © 2013 Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.